Levosimendan in Europe and China: An Appraisal of Evidence and Context
The calcium sensitiser levosimendan (SIMDAX; Orion Pharma) has been in clinical use for the management of acute heart failure and a range of related syndromes in many countries around the world for two decades. More recently, levosimendan has become available in China. The authors have examined the...
Enregistré dans:
Auteurs principaux: | Xiangqing Kong, Xinqun Hu, Baotong Hua, Francesco Fedele, Dimitrios Farmakis, Piero Pollesello |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Radcliffe Medical Media
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/d6ea5947bafb402f8d01baee6e6bf6a7 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Haemodynamic Balance in Acute and Advanced Heart Failure: An Expert Perspective on the Role of Levosimendan
par: Piergiuseppe Agostoni, et autres
Publié: (2019) -
Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use
par: Zoltán Papp, et autres
Publié: (2020) -
Role of Levosimendan in acute decompensated heart failure
par: V.K. Katyal, et autres
Publié: (2021) -
Escalating incidence of infective endocarditis in Europe in the 21st century
par: Nandan S Anavekar, et autres
Publié: (2021) -
The DAPA Trial in the Context of Previous Prophylactic ICD Landmark Trials
par: Danielle Haanschoten, et autres
Publié: (2021)